| Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes (NCT00352001) | Mikkael Sekeres MD | 2006-05-01 |
| Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant (NCT00324324) | OHSU Knight Cancer Institute | 2006-05-01 |
| Identifying Characteristics of Bone Marrow Failure Syndromes (NCT00315419) | Office of Rare Diseases (ORD) | 2006-04-01 |
| Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer (NCT00346359) | Fred Hutchinson Cancer Center | 2006-03-01 |
| Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers. (NCT00354172) | Masonic Cancer Center, University of Minnesota | 2006-02-01 |
| Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant (NCT00281814) | The Cleveland Clinic | 2006-02-01 |
| Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation (NCT00281801) | Case Comprehensive Cancer Center | 2006-02-01 |
| Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS) (NCT00303472) | Amgen | 2006-02-01 |
| Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer (NCT00281879) | OHSU Knight Cancer Institute | 2006-02-01 |
| Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes (NCT00380653) | Cyclacel Pharmaceuticals, Inc. | 2006-01-01 |
| Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) (NCT00255346) | M.D. Anderson Cancer Center | 2005-11-15 |
| VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia (NCT00083187) | Vion Pharmaceuticals | 2005-11-01 |
| Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation (NCT00328237) | Colorado Blood Cancer Institute | 2005-11-01 |
| Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia (NCT00357565) | Masonic Cancer Center, University of Minnesota | 2005-11-01 |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease (NCT00719849) | Fred Hutchinson Cancer Center | 2005-11-01 |
| RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes (NCT00809185) | Case Comprehensive Cancer Center | 2005-11-01 |
| Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen (NCT00448357) | UNC Lineberger Comprehensive Cancer Center | 2005-10-01 |
| Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder (NCT00274820) | Case Comprehensive Cancer Center | 2005-10-01 |
| Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients (NCT00117507) | Novartis Pharmaceuticals | 2005-09-01 |
| Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil (NCT00608517) | Vanderbilt-Ingram Cancer Center | 2005-09-01 |
| A Standardized Nursing Intervention Protocol for HCT Patients (NCT00951626) | City of Hope Medical Center | 2005-09-01 |
| Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes (NCT00803530) | Fondazione Italiana Sindromi Mielodisplastiche-ETS | 2005-09-01 |
| AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders (NCT00547196) | City of Hope Medical Center | 2005-08-16 |
| Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS (NCT00334074) | Baylor Research Institute | 2005-08-01 |
| Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) (NCT00361140) | H. Lee Moffitt Cancer Center and Research Institute | 2005-08-01 |
| Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases (NCT00309842) | Masonic Cancer Center, University of Minnesota | 2005-07-28 |
| A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome (NCT00217594) | National Heart, Lung, and Blood Institute (NHLBI) | 2005-07-21 |
| Metoclopramide to Treat Anemia in Patients With Myelodysplastic Syndrome (MDS) (NCT00120653) | National Heart, Lung, and Blood Institute (NHLBI) | 2005-07-14 |
| Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality (NCT00179621) | Celgene Corporation | 2005-07-01 |
| Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia (NCT00618696) | Masonic Cancer Center, University of Minnesota | 2005-07-01 |
| Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease (NCT00392782) | Masonic Cancer Center, University of Minnesota | 2005-07-01 |
| Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease (NCT00462657) | St. Bartholomew's Hospital | 2005-07-01 |
| Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant (NCT00321932) | University of Minnesota | 2005-07-01 |
| Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer (NCT00611351) | University of Nebraska | 2005-06-07 |
| Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome (NCT00253513) | OHSU Knight Cancer Institute | 2005-06-01 |
| Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer (NCT00295880) | Masonic Cancer Center, University of Minnesota | 2005-06-01 |
| Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant (NCT00305682) | Masonic Cancer Center, University of Minnesota | 2005-06-01 |
| MK0457 in Patients With Leukemia (0457-003) (NCT00111683) | Merck Sharp & Dohme LLC | 2005-06-01 |
| Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (NCT00245037) | OHSU Knight Cancer Institute | 2005-06-01 |
| Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant (NCT00376480) | Dana-Farber Cancer Institute | 2005-06-01 |
| Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases (NCT00317785) | Fred Hutchinson Cancer Center | 2005-05-01 |
| Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer (NCT00818961) | Northside Hospital, Inc. | 2005-05-01 |
| Bortezomib in Treating Patients With Myelodysplastic Syndromes (NCT00262873) | University of Rochester | 2005-05-01 |
| Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain (NCT00666211) | Vanderbilt-Ingram Cancer Center | 2005-05-01 |
| Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia (NCT00295997) | University of California, San Francisco | 2005-05-01 |
| Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders (NCT00114257) | National Cancer Institute (NCI) | 2005-05-01 |
| Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) (NCT00109538) | Merck Sharp & Dohme LLC | 2005-05-01 |
| SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes. (NCT00113893) | Scios, Inc. | 2005-05-01 |
| Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia (NCT00118196) | Medical University of South Carolina | 2005-04-01 |
| Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease (NCT00295971) | University of California, San Francisco | 2005-04-01 |
| T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) (NCT00242515) | National University Hospital, Singapore | 2005-03-01 |
| Unrelated Donor Stem Cell Transplantation (NCT01364363) | Scripps Health | 2005-03-01 |
| Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (NCT00104975) | Yale University | 2005-02-01 |
| A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes (NCT00324129) | Mirati Therapeutics Inc. | 2005-02-01 |
| A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes (NCT00324194) | Mirati Therapeutics Inc. | 2005-02-01 |
| A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) (NCT00100152) | Merck Sharp & Dohme LLC | 2005-02-01 |
| Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (NCT00121303) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2005-01-01 |
| Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes (NCT00098683) | Children's Oncology Group | 2005-01-01 |
| Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders (NCT00301834) | University of California, San Francisco | 2005-01-01 |
| The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality (NCT00874978) | King's College Hospital NHS Trust | 2005-01-01 |
| Campath-1H + FK506 and Methylprednisolone for GVHD (NCT00109993) | Case Comprehensive Cancer Center | 2005-01-01 |
| Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes (NCT00102687) | Celgene | 2005-01-01 |
| Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes (NCT00104806) | Wake Forest University Health Sciences | 2004-11-01 |
| Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer (NCT00134004) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2004-10-01 |
| Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS) (NCT00234143) | St. Bartholomew's Hospital | 2004-10-01 |
| Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant (NCT00293384) | Barbara Ann Karmanos Cancer Institute | 2004-10-01 |
| A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome (NCT00095264) | Amgen | 2004-10-01 |
| Low Dose Melphalan and Bortezomib for AML and High-Risk MDS (NCT00789256) | Dartmouth-Hitchcock Medical Center | 2004-09-01 |
| Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer (NCT00301951) | University of California, San Francisco | 2004-09-01 |
| Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation (NCT00096096) | Fred Hutchinson Cancer Center | 2004-08-01 |
| TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD (NCT00185796) | Stanford University | 2004-07-01 |
| Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer (NCT00134017) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2004-06-01 |
| Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes (NCT00093366) | Fred Hutchinson Cancer Center | 2004-06-01 |
| Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) (NCT00086125) | Merck Sharp & Dohme LLC | 2004-06-01 |
| Dose-reduced Versus Standard Conditioning in MDS/sAML (NCT01203228) | European Society for Blood and Marrow Transplantation | 2004-05-01 |
| G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders (NCT00253552) | OHSU Knight Cancer Institute | 2004-05-01 |
| Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies (NCT00241358) | Washington University School of Medicine | 2004-05-01 |
| Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease (NCT00521430) | Asan Medical Center | 2004-04-01 |
| Collecting and Storing Blood Samples From Patients With Cancer (NCT00900120) | University of Medicine and Dentistry of New Jersey | 2004-03-01 |
| Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes (NCT00451997) | M.D. Anderson Cancer Center | 2004-03-01 |
| Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes (NCT00217386) | Fred Hutchinson Cancer Center | 2004-03-01 |
| T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies (NCT00080925) | National Institutes of Health Clinical Center (CC) | 2004-02-01 |
| Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes (NCT00075010) | M.D. Anderson Cancer Center | 2004-01-23 |
| 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome (NCT00077558) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2004-01-01 |
| T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases (NCT00589602) | The Cleveland Clinic | 2004-01-01 |
| Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes (NCT00072475) | Alliance for Clinical Trials in Oncology | 2003-12-01 |
| Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer (NCT00255684) | University of Rochester | 2003-12-01 |
| Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation (NCT00144677) | Dana-Farber Cancer Institute | 2003-11-01 |
| A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS) (NCT00072969) | National Heart, Lung, and Blood Institute (NHLBI) | 2003-11-01 |
| Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome (NCT00077116) | European Organisation for Research and Treatment of Cancer - EORTC | 2003-11-01 |
| A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care (NCT00071799) | Celgene | 2003-11-01 |
| Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant (NCT00534118) | Roswell Park Cancer Institute | 2003-10-01 |
| Infliximab in Treating Patients With Myelodysplastic Syndrome (NCT00074074) | European Organisation for Research and Treatment of Cancer - EORTC | 2003-10-01 |
| Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases (NCT00084695) | Milton S. Hershey Medical Center | 2003-09-01 |
| Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease (NCT00118326) | Fred Hutchinson Cancer Center | 2003-08-01 |
| Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia (NCT06956755) | Groupe Francophone des Myelodysplasies | 2003-07-07 |
| Cholecalciferol in Treating Patients With Myelodysplastic Syndrome (NCT00068276) | Wake Forest University Health Sciences | 2003-07-01 |
| Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy (NCT00066599) | National Cancer Institute (NCI) | 2003-06-01 |
| Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation (NCT00064311) | National Institutes of Health Clinical Center (CC) | 2003-06-01 |
| Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes (NCT00064974) | Celgene Corporation | 2003-06-01 |